- $521.22m
- $286.53m
- $83.33m
- 52
- 16
- 63
- 39
Annual income statement for Regenxbio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 155 | 470 | 113 | 90.2 | 83.3 |
| Cost of Revenue | |||||
| Gross Profit | 119 | 419 | 58.2 | 53 | 49.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 274 | 310 | 376 | 358 | 317 |
| Operating Profit | -119 | 160 | -263 | -268 | -233 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -106 | 141 | -280 | -264 | -227 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -111 | 128 | -280 | -263 | -227 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -111 | 128 | -280 | -263 | -227 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -111 | 128 | -280 | -263 | -227 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.98 | 2.91 | -6.5 | -6.02 | -4.54 |